In eyes with glaucoma, as well as in healthy eyes, femtosecond laser-assisted cataract surgery leads to an initial IOP rise, followed by significant decrease at 1 month. Reduction is sustained in eyes with glaucoma over 3 years, according to a study.
The effects of cataract surgery on IOP are well known, and cataract surgery is often used as a way of managing glaucoma. However, it is not known whether femtosecond-assisted surgery has effects comparable to standard phacoemulsification.
A group of researchers at the University of Colorado performed a retrospective study on 504 eyes that underwent the femtosecond laser-assisted procedure between February 2012 and April 2015; 278 had a preoperative diagnosis of glaucoma or glaucoma suspect and 226 were healthy controls.
Both the glaucoma/glaucoma suspect group and the control group had an initial mean increase in IOP at day 1. Spikes of 10 mm Hg or 20 mm Hg were uncommon but were more than twice as frequent in the glaucoma/glaucoma suspect group, where mean IOP elevation was higher overall. At 1 week, IOP was back to baseline values, and at 1 month both groups had a significant decrease in IOP as compared with baseline. This decrease was maintained for 1 year in the healthy eyes and over the entire follow-up of 3 years in eyes with glaucoma/glaucoma suspect.
The soft or rigid patient interface of the femtosecond lasers used in the study did not have a different effect on IOP elevation. In several eyes operated before June 2014, a rigid applanator was used, while all subsequent cases were performed with the soft applanator.
“Despite the intraoperative differences in IOP noted in previous studies, we found no significant difference in long-term IOP at any postoperative timepoint,” the authors wrote.
Further, prospective studies evaluating glaucoma progression after femtosecond laser-assisted cataract surgery are warranted, the authors. – by Michela Cimberle
Disclosure: Shah reported no relevant financial disclosures. Please see the published paper for the other authors’ financial disclosures.